Featured

An AMAZING new medicine has either already been released or just coming out. That is the claim in all the TV advertisements and pharmaceutical detail men and women. We have a new drug that is non-inferior to something else, so it has to be good. Often the question is: is it better, safer, cost-effective, has […]

New Data Forecast More Oral PDE4 Inhibitors for Psoriasis Medscape 3/24/2023 Orismilast is a new Phosphodiesterase-4 inhibitor, in phase two trials showing promise, is said to be 2 – 5 times more effective than those on the market. The chief competitor will be Daliresp (roflumilast), now generic, that is available for $35/month from Walmart. Another